Cancer treatment often involves multiple options based on general data about how most patients will respond to therapy. However, this approach may not be effective for everyone, as treatment responses and side…
Read More ➝
November is Prostate Cancer Awareness Month, so this month we’ve interviewed MiraKind’s founder, Dr. Joanne Weidhaas, about personalizing prostate cancer treatment and how patients can personalize their treatment choices with a new…
Read More ➝
In November 2020, we announced that we had undertaken new research into other genetic variants that are connected to cancer. Specifically, ones that affect prostate cancer.1 Our research has produced a lot…
Read More ➝
Over the years, Mirakind has shared research and information about the KRAS-variant and how it can have many health implications – from cancer to autoimmunity to response to hormone replacement therapy. Now,…
Read More ➝
Disclaimer
Any discussion of medical management options on this website is for general informational purposes only and does not constitute a medical recommendation. All medical management decisions should be made based on consultation between each patient and his or her healthcare professional.
